文献速递消化系统肿瘤

直肠癌接受或不接受放疗后第二肿瘤的发生率

Incidence of second tumors after treatment with or without radiation for rectal cancer.
PubMed 文献 · Ann Oncol · 2017-01-01

该研究基于荷兰人群癌症登记资料,纳入1989—2007年确诊并接受手术的非转移性原发性直肠癌患者29027例,其中15467例接受放疗,中位随访7.7年。结果显示,直肠癌患者任何第二肿瘤的标化发病风险为1.16(95%CI 1.12-1.19),放疗与盆腔第二肿瘤累积发生率降低相关(SHR 0.77,95%CI 0.68-0.88)。

要点

  • 直肠癌患者任何第二肿瘤的标化发病风险为1.16(95%CI 1.12-1.19),较一般人群每年每万例多27.7例。
  • 接受放疗者盆腔第二肿瘤累积发生率低于未接受放疗者(SHR 0.77,95%CI 0.68-0.88)。
  • 接受放疗者前列腺第二肿瘤更少见(SHR 0.54,95%CI 0.46-0.64),妇科肿瘤更多见(SHR 1.49,95%CI 1.11-2.00)。

核心结论

  • 既往直肠癌患者发生第二肿瘤的风险较一般人群略有升高。
  • 接受放疗的女性中妇科肿瘤发生更频繁,但未导致第二癌症总体风险升高。
  • 放疗似乎对其它盆腔第二肿瘤的发生具有保护作用,以前列腺癌为主。
  • 作者认为这些发现很重要,有助于改善对患者的咨询。

研究设计与样本

  • 研究数据来自荷兰基于人群的癌症登记,纳入1989—2007年确诊的所有接受手术治疗的非转移性原发性直肠癌患者。
  • 采用Fine和Gray竞争风险模型估算第二肿瘤的累积发生率,并使用Cox回归进行多因素分析。
  • 队列共29027例患者,其中15467例接受过放疗;中位随访7.7年(范围0-27年)。

主要发现

  • 全部4398例被诊断为第二原发肿瘤的患者中,1030例发生一个或多个盆腔肿瘤。
  • 任何第二肿瘤的标化发病风险为1.16(95%CI 1.12-1.19),与一般人群相比,接受直肠癌治疗的患者每年每万例中多出27.7例癌症病例。
  • 与未接受放疗的患者相比,放疗降低了盆腔第二肿瘤的累积发生率(SHR 0.77,95%CI 0.68-0.88)。
  • 接受放疗者前列腺第二肿瘤更少见(SHR 0.54,95%CI 0.46-0.64);接受放疗者妇科肿瘤更常见(SHR 1.49,95%CI 1.11-2.00)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The aim of this study was to analyze the association between radiation therapy (RT) for rectal cancer and the development of second tumors. PATIENTS AND METHODS: Data on all surgically treated non-metastatic primary rectal cancer patients diagnosed between 1989 and 2007 were retrieved from the Netherlands population-based cancer registry. Fine and Gray's competing risk model was used for estimation of the cumulative incidence of second tumors. Multivariable analysis was conducted using Cox regression. RESULTS: The cohort consisted of 29 027 patients of which 15 467 patients had undergone RT. Median follow-up was 7.7 years (range 0-27). Among all 4398 patients who were diagnosed with a second primary tumor, 1030 had one or more pelvic tumors. The standardized incidence risk for any second tumor was 1.16 (95% confidence interval [CI] 1.12-1.19), resulting in 27.7/10 000 excess cancer cases per year in patients treated for rectal cancer compared with the general population. RT reduced the cumulative incidence of second pelvic tumors compared with patients who did not receive RT (subhazard ratio [SHR] 0.77, CI 0.68-0.88). Second prostate tumors were less common in patients who received RT (SHR 0.54, CI 0.46-0.64), gynecological tumors were more frequently observed in patients who received RT (SHR 1.49, CI 1.11-2.00). CONCLUSIONS: Patients with previous rectal cancer had a marginally increased risk of a second tumor compared with the general population. Gynecological tumors occurred more often in females who received RT, but this did not result in an overall increased risk for a second cancer. RT even seemed to have a protective effect on the development of other second pelvic tumors, pre-dominantly for prostate cancer. These findings are highly important and can contribute to improved patient counseling.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Rombouts AJM, Hugen N, Elferink MAG, et al. Incidence of second tumors after treatment with or without radiation for rectal cancer. Ann Oncol. 2017. PMID: 27993790. doi:10.1093/annonc/mdw661

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。